Quickly identifying genetic mutations in acute myeloid leukemia using advanced sequencing techniques
Official title: Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
Funded at Fred Hutchinson Cancer Center · NIH-10815759 · Data updated 2026-11-12
This study is testing a new, faster way to find genetic changes in acute myeloid leukemia (AML) to help doctors quickly understand how serious the disease is and choose the best treatment for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $187,058 |
| NIH project number | 5R21CA280520-02 |
| Project ID | NIH-10815759 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who require genetic profiling for treatment decisions.
✕Less likely to help
Patients with other types of leukemia or those who do not have genetic mutations relevant to the study may not benefit from this research.
What this research studies
This research focuses on improving the detection of genetic mutations and fusions in acute myeloid leukemia (AML) using a novel CRISPR-based sequencing method. By employing a single molecule long-read sequencing assay, the study aims to provide rapid results that can help in the timely stratification of patient risk and selection of appropriate treatments. The approach seeks to overcome limitations of traditional sequencing methods, allowing for same-day results that could significantly enhance patient care. The research will evaluate the effectiveness of this new method in identifying mutations and assessing tumor burden compared to existing techniques.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate diagnosis and treatment selection for patients with acute myeloid leukemia.
How similar studies have gone: Other research has shown promise in using advanced sequencing techniques for cancer diagnosis, suggesting that this approach could be a significant advancement in the field.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Yeung, Cecilia C — Fred Hutchinson Cancer Center
- Study coordinator: Yeung, Cecilia C
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Reducing leukemia disparities in Latino children and teens
A large, multi-project effort aims to understand why Latino children with acute lymphoblastic leukemia have worse outcomes and how to reduce those gaps.
-
Genomic advances to improve outcomes in high-risk acute leukemia
A physician-scientist team is studying the genetic drivers of pediatric acute leukemia to find new ways to diagnose and treat it, with the goal of improving cure rates for kids.
-
Understanding and Targeting Extramedullary Acute Leukemia
A clinician-research team is studying myeloid sarcoma, a form of AML that forms solid tumors outside the bone marrow, to develop new treatments for patients.
-
Diversifying acute leukemia trial enrollment through multilevel approach
Aiming to broaden participation in acute leukemia trials by testing a multi-layer plan that addresses barriers for adults with AML.
-
Blocking menin to treat acute leukemias with high HOX gene activity
This work develops new drugs that block a protein called menin to help people with certain aggressive acute leukemias driven by HOX gene activation.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.